治疗干眼症新药lifitegrast

发布时间：2018-07-10 15:59

  本文选题：干眼症 + 眼部炎症　； 参考：《中国新药杂志》2017年11期

【摘要】：lifitegrast是一种新型小分子T细胞抑制剂,通过影响细胞粘附分子(ICAM-1)与淋巴细胞功能相关抗原(LFA-1)的结合,有效阻断炎症通路,抑制T细胞介导的炎症反应,从而改善干眼症患者的症状与体征。多项动物试验及临床研究显示,lifitegrast具有良好的安全性和耐受性。2016年7月美国FDA批准其上市,用于干眼症的治疗。本文对其药理作用、药动学、临床研究及安全性等进行综述。
[Abstract]:Lifitegrast is a new type of small molecule T cell inhibitor. By affecting the binding of ICAM-1 to lymphocyte function related antigen (LFA-1), lifitegrast effectively blocks the inflammatory pathway and inhibits the inflammatory response mediated by T cells. So as to improve the symptoms and signs of patients with xerophthalmia. A number of animal trials and clinical studies have shown that lifitegrast is safe and well tolerated. In July 2016, the FDA approved its launch for dry eye treatment. The pharmacological action, pharmacokinetics, clinical research and safety of the drug were reviewed in this paper.
【作者单位】： 上海交通大学医学院附属仁济医院药学部;
【分类号】：R988.1
，

本文编号：2113880